Sang Geon Kim
Overview
Explore the profile of Sang Geon Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
211
Citations
3737
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Lee E, Nam T, You S, Im D, Kim K, et al.
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006537
(AM), which belongs to the daisy family Asteraceae, has a longstanding traditional use in Europe and North America for pain and inflammation treatment. This study investigates the inhibitory effects of...
2.
Nguyen M, Lee G, Kim B, Kim H, Tak J, Park M, et al.
Pharmacol Res
. 2024 Dec;
210:107512.
PMID: 39643070
Hepatocellular carcinoma (HCC) comprises the majority of primary liver cancers and possesses a low 5-year survival rate when in the advanced stages. Anillin (ANLN), a key player in cell growth...
3.
Khan M, Tak J, Kim Y, Lee S, Lee E, Kim S
Life Sci
. 2024 Nov;
360:123180.
PMID: 39561875
Aims: Hyperglycemia induces pathophysiological changes. Endoplasmic reticulum (ER) stress with Gα overexpression may promote hepatocyte death. This study investigated whether sustained hyperglycemia triggers ER stress-associated pyroptosis and fibrosis in the...
4.
Yoon J, Song H, Park J, Kim J, Jun Y, Gim S, et al.
Biomed Pharmacother
. 2024 Nov;
181:117674.
PMID: 39536537
Fasiglifam, a candidate targeting GPR40, showed efficacy in clinical trials for type 2 diabetes but exerted liver toxicity. This study investigated the drug-induced liver injury (DILI) risk of Xelaglifam, a...
5.
Tak J, Kim Y, Kim S
Clin Mol Hepatol
. 2024 Oct;
31(1):1-31.
PMID: 39355873
The prevalence of drug-induced liver injury (DILI) and viral liver infections presents significant challenges in modern healthcare and contributes to considerable morbidity and mortality worldwide. Concurrently, metabolic dysfunctionassociated steatotic liver...
6.
Kwon S, Kim Y, Tak J, Lee S, Lee E, Kim S
Sci Rep
. 2024 Aug;
14(1):19580.
PMID: 39179591
Inflammatory bowel disease is defined by inflammation and immune dysregulation. This study investigated the effects of Gα13 liver-specific knockout (LKO) on proximal and distal colons of dextran sodium sulfate (DSS)-induced...
7.
Kato Y, Ariyoshi K, Nohara Y, Matsunaga N, Shimauchi T, Shindo N, et al.
Br J Pharmacol
. 2024 Jul;
181(21):4328-4347.
PMID: 38986570
Background And Purpose: Maintaining mitochondrial quality is attracting attention as a new strategy to treat diabetes and diabetic complications. We previously reported that mitochondrial hyperfission by forming a protein complex...
8.
Yoon J, Lee D, Song H, Hong D, Park J, Hong C, et al.
Biomed Pharmacother
. 2024 Jun;
177:117044.
PMID: 38941892
Xelaglifam, developed as a GPR40/FFAR1 agonist, induces glucose-dependent insulin secretion and reduces circulating glucose levels for Type 2 diabetes treatment. This study investigated the effects of Xelaglifam in comparison with...
9.
Sharma G, Sharma A, Kim I, Cha D, Kim S, Park E, et al.
Nat Immunol
. 2024 Apr;
25(5):790-801.
PMID: 38664585
Innate immune cells generate a multifaceted antitumor immune response, including the conservation of essential nutrients such as iron. These cells can be modulated by commensal bacteria; however, identifying and understanding...
10.
Tak J, Nguyen T, Lee K, Kim S, Ahn H
Biomed Pharmacother
. 2024 Mar;
174:116459.
PMID: 38518599
Ubiquitin-specific protease (USP), an enzyme catalyzing protein deubiquitination, is involved in biological processes related to metabolic disorders and cancer proliferation. We focused on constructing predictive models tailored to unveil compounds...